Esperion Therapeutics traded at $6.68 this Thursday July 7th, decreasing $0.01 or 0.13 percent since the previous trading session. Looking back, over the last four weeks, Esperion Therapeutics lost 7.76 percent. Over the last 12 months, its price fell by 65.29 percent. Looking ahead, we forecast Esperion Therapeutics to be priced at 6.28 by the end of this quarter and at 5.78 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
6.68
Daily Change
-0.13%
Yearly
-65.29%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Daiichi Sankyo 3,521.00 46.00 1.32% 55.04%
AbbVie 150.69 -1.84 -1.21% 29.07%
Alnylam Pharmaceuticals 150.00 -0.73 -0.48% -13.09%
Amgen 245.60 0.35 0.14% 0.54%
Amarin 1.61 0.05 3.21% -62.12%
Biogen 218.06 2.08 0.96% -40.91%
BioMarin Pharmaceutical 86.41 0.05 0.06% 4.06%
Cytokinetics 44.14 0.24 0.55% 123.27%
Esperion Therapeutics 6.68 -0.01 -0.13% -65.29%
Geron 1.86 0 0% 37.78%
Halozyme Therapeutics 47.07 0.32 0.68% 3.18%
Heron Therapeutics 3.16 0.02 0.48% -77.66%
Intercept Pharmaceuticals 13.85 -1.44 -9.42% -27.03%
Ionis Pharmaceuticals 37.09 0.28 0.75% -4.81%
Intra Cellular Therapies 58.16 1.99 3.53% 41.84%
Eli Lilly 327.73 -2.42 -0.73% 38.21%
Merck & Co 93.20 0.07 0.08% 19.30%
Moderna Inc 166.76 7.20 4.51% -28.36%
Minerva Neurosciences 3.21 -0.04 -1.23% 38.96%
Nektar Therapeutics 3.90 -0.03 -0.76% -76.53%
Puma Biotechnology 2.78 0.12 4.51% -66.34%
Pfizer 53.20 0.45 0.85% 35.54%
PTC Therapeutics 42.91 -0.87 -1.99% -2.57%
Regeneron Pharmaceuticals 600.30 5.40 0.91% 4.41%
Sanofi 98.66 0.76 0.78% 15.02%
Seattle Genetics 175.13 -1.64 -0.93% 16.96%
Sarepta Therapeutics 75.97 0.23 0.30% 5.53%
United Therapeutics 241.90 4.75 2.00% 29.37%
Vanda Pharmaceuticals 11.69 0.19 1.65% -42.10%

Indexes Price Day Year
USND 11481 119.21 1.05% -21.15%
US2000 1756 28.56 1.65% -21.31%

Esperion Therapeutics
Esperion Therapeutics, Inc. is a lipid management company. The Company is a pharmaceutical company focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease (ASCVD), or heterozygous familial hypercholesterolemia (HeFH). Its products include NEXLETOL, NILEMDO, NEXLIZET and NUSTENDI. NEXLETOL and NILEMDO are ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. NEXLIZET and NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.